Pfizer: Partners With Insilico To Identify Drug Targets
- According to the biotechnology publishing firm, FierceBiotech, this partnership will leverage Pfizer to use Insilico’s technology
- Insilico AI-based drug discovery has recently developed a treatment for a disease named fibrosis in less than 30 days
- Insilico had tied up with GlaxoSmithKline, a British multinational pharmaceutical firm, to discover molecules and new targets
- This tie-up also may increase the opportunities for other budding startups
- According to MarketWatch, pharma and biotech firms also have spent over $342B on M&A ventures as per the records of December 2019
- Moreover, Pharmaceutical companies spend over $2.6 billion in testing and trials of drugs
